Friday, April 26, 2024
FibroBiologics, Inc. (Nasdaq: FBLG) and Charles River Laboratories have announced a letter of intent, marking the beginning of a collaboration. The agreement paves the way for the transfer, testing, and validation of FibroBiologics’ technology, with plans for a comprehensive master services agreement in the pipeline. This agreement will cover the development and manufacture of FibroBiologics’ master cell bank, working cell bank, and fibroblast-based spheroids for clinical trials.
FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. Their research explores the immunomodulatory and regenerative properties of these materials for conditions such as degenerative disc disease, multiple sclerosis, wound healing, psoriasis, thymic involution reversal, and cancer.
Charles River Laboratories, renowned for its expertise in drug discovery, development, and manufacturing solutions, will conduct feasibility studies on FibroBiologics' cell manufacturing processes. Pending the master services agreement, Charles River will act as the contract development and manufacturing organization (CDMO) responsible for producing drug products for specific clinical trials.
With a focus on simplifying complex supply chains and meeting the increasing demand for cell and gene therapy services, Charles River has expanded its portfolio in recent years. Leveraging its legacy testing capabilities, Charles River offers a comprehensive solution from initial concept to final therapy.
FibroBiologics, expressed enthusiasm about the collaboration, highlighting Charles River's leadership in cell and gene therapy development and manufacturing. Both companies share a commitment to delivering innovative therapies to patients suffering from chronic diseases.
Source: globenewswire.com
